MedTrace Logo

Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients

NCT04616209 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2025-02-14

No results posted yet for this study

Summary

Objectives: To determine the safety, tolerability, and efficacy of allogeneic PB103 in patients with IIIb/IV or refractory non-small-cell lung cancer

Conditions

Interventions

BIOLOGICAL

donor-derived NK cell infusion

PB103 administrations will be separated by 4-week interval

Sponsors & Collaborators

  • Tri-Service General Hospital

    collaborator OTHER

  • Precision Biotech Taiwan Corp.

    lead INDUSTRY

Principal Investigators

  • Ming-Shen Dai, MD/PhD · Tri-Service General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-15
Primary Completion
2027-12-30
Completion
2027-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04616209 on ClinicalTrials.gov